Cardiac Science Ranked Fourth Fastest Growing Technology Company in North America on the Deloitte Technology Fast 500 Program
25 October 2004 - 4:30PM
PR Newswire (US)
Cardiac Science Ranked Fourth Fastest Growing Technology Company in
North America on the Deloitte Technology Fast 500 Program Revenue
Growth Attributed to Entry Into AED Market IRVINE, Calif., Oct. 25
/PRNewswire-FirstCall/ -- Cardiac Science Inc. (NASDAQ:DFIB), a
leading manufacturer of life-saving automatic public access
defibrillators (AEDs), today announced that it ranked No. 4 on the
2004 Deloitte Technology Fast 500, a ranking of the 500 fastest
growing technology companies in North America. Rankings are based
on percentage revenue growth over five years, from 1999-2003.
Cardiac Science grew 60,077 percent during this period. Cardiac
Science's Chairman & CEO Raymond W. Cohen credits the Cardiac
Science employees, partners and distributors with combining forces
and establishing the Powerheart(R) brand as a leading choice in
AEDs. He said, "Our strategic decision to enter the public access
AED market came at a pivotal time as growth in that segment began
to accelerate." "Growing the top line enough to make the Deloitte
Technology Fast 500 is especially meaningful during tough economic
times for the technology sector," said Mark A. Evans, national
managing partner of Deloitte's Technology, Media &
Telecommunications Group. "We congratulate Cardiac Science on
becoming one of the 500 fastest growing technology companies in
North America." In addition to ranking on the Deloitte Technology
Fast 500, Cardiac Science ranked No. 1 on the Orange County
Technology Fast 50, which is a ranking of the 50 fastest growing
technology firms in Orange County. Fast 500 Selection and
Qualifications The Fast 500 list is compiled from Deloitte's 19
regional North American Fast 50 programs, nominations submitted
directly to the Fast 500, and public company database research. To
qualify for the Fast 500, entrants must have had 1999 operating
revenues of at least $50,000 USD and $75,000 CD for the United
States and Canada, respectively; and 2003 operating revenues must
be at least $1 million USD or CD. Entrants must also be public or
private companies headquartered in North America and must be a
"technology company," defined as a company that owns proprietary
technology that contributes to a significant portion of the
company's operating revenues; or devotes a significant proportion
of revenues to the research and development of technology. Using
other companies' technology in a unique way does not qualify. About
Cardiac Science Cardiac Science develops, manufactures and markets
Powerheart(R)-brand public-access defibrillators (AEDs) and offers
comprehensive AED/CPR training and AED program management services
that facilitate successful deployments. The Company also makes the
Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient
monitor that instantly and automatically treats hospitalized
cardiac patients who suffer life-threatening heart rhythms. Cardiac
Science also manufactures its AED products on a private label basis
for other leading medical companies. For more information, please
visit http://www.cardiacscience.com/, email Cardiac Science at or
call 1-949-797-3800. About Deloitte Deloitte refers to one or more
of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and
their respective subsidiaries and affiliates. As a Swiss Verein
(association), neither Deloitte Touche Tohmatsu nor any of its
member firms has any liability for each other's acts or omissions.
Each of the member firms is a separate and independent legal entity
operating under the names "Deloitte," "Deloitte & Touche,"
"Deloitte Touche Tohmatsu," or other related names. Services are
provided by the member firms or their subsidiaries or affiliates
and not by the Deloitte Touche Tohmatsu Verein. Deloitte &
Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu.
In the U.S., services are provided by the subsidiaries of Deloitte
& Touche USA LLP (Deloitte & Touche LLP, Deloitte
Consulting LLP, Deloitte Tax LLP, and their subsidiaries), and not
by Deloitte & Touche USA LLP. For further information please
contact: Matt Clawson (Investors), , or Len Hall (Media), , both of
Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.;
or Raymond W. Cohen, Chief Executive Officer of Cardiac Science,
Inc., +1-949-797-3800, DATASOURCE: Cardiac Science, Inc. CONTACT:
Matt Clawson (Investors), , or Len Hall (Media), , both of Allen
& Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or
Raymond W. Cohen, Chief Executive Officer of Cardiac Science, Inc.,
+1-949-797-3800, Web site: http://www.cardiacscience.com/
Copyright
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Oct 2023 to Oct 2024